Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (41-50 of 179) with videos related to

Pageof 18
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Annals of Hematology|January 30, 2015
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphomaMyron S Czuczman, Stephen Kahanic, Andres Forero, et al.
JCO Clinical Cancer Informatics|March 7, 2019
Visualization of Sequential Treatments in Metastatic Breast CancerGabrielle B Rocque, Pravinkumar G Kandhare, Courtney P Williams, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2010
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)Andres Forero-Torres, Jatin Shah, Tina Wood, et al.
Journal of Oncology Practice|May 19, 2016
Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical TrialsMona N Fouad, Aras Acemgil, Sejong Bae, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2019
Histone deacetylase inhibition promotes intratumoral CD8<sup>+</sup> T-cell responses, sensitizing murine breast tumors to anti-PD1Tyler R McCaw, Mei Li, Dmytro Starenki, et al.
Breast Cancer Research and Treatment|April 3, 2015
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancersJennifer Stanley, Lisa Klepczyk, Kimberly Keene, et al.
Southern Medical Journal|November 3, 2020
Less Toxic Chemotherapy in Locally Advanced Breast CancerJohn Carpenter, Andres Forero, Carla I Falkson, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 30, 2007
Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicityPierre L Triozzi, Jatin J Shah, Wen-Quan Wang, et al.
Breast Cancer Research and Treatment|September 9, 2011
Effect of anti-DR5 and chemotherapy on basal-like breast cancerPatsy G Oliver, Albert F LoBuglio, Tong Zhou, et al.
Pageof 18

Showing results (41-50 of 179) with videos related to

Sort By:
Pageof 18
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Annals of Hematology|January 30, 2015
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphomaMyron S Czuczman, Stephen Kahanic, Andres Forero, et al.
JCO Clinical Cancer Informatics|March 7, 2019
Visualization of Sequential Treatments in Metastatic Breast CancerGabrielle B Rocque, Pravinkumar G Kandhare, Courtney P Williams, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2010
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)Andres Forero-Torres, Jatin Shah, Tina Wood, et al.
Journal of Oncology Practice|May 19, 2016
Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical TrialsMona N Fouad, Aras Acemgil, Sejong Bae, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2019
Histone deacetylase inhibition promotes intratumoral CD8<sup>+</sup> T-cell responses, sensitizing murine breast tumors to anti-PD1Tyler R McCaw, Mei Li, Dmytro Starenki, et al.
Breast Cancer Research and Treatment|April 3, 2015
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancersJennifer Stanley, Lisa Klepczyk, Kimberly Keene, et al.
Southern Medical Journal|November 3, 2020
Less Toxic Chemotherapy in Locally Advanced Breast CancerJohn Carpenter, Andres Forero, Carla I Falkson, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 30, 2007
Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicityPierre L Triozzi, Jatin J Shah, Wen-Quan Wang, et al.
Breast Cancer Research and Treatment|September 9, 2011
Effect of anti-DR5 and chemotherapy on basal-like breast cancerPatsy G Oliver, Albert F LoBuglio, Tong Zhou, et al.
Pageof 18